{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T10:24:22Z","timestamp":1777717462505,"version":"3.51.4"},"reference-count":28,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Toxicol"],"published-print":{"date-parts":[[2005,9]]},"abstract":"<jats:p>This study was conducted in support of the International Life Sciences Institute (ILSI) alternative carcinogenicity models initiative to evaluate the carcinogenic potential of clofibrate, a nongenotoxic peroxisome proliferator-activated receptor (PPAR) \u03b1 agonist, following oral administration to neonatal mice. Male and female neonatal CD-1 mice were dosed with clofibrate at doses of 100, 250, and 500 mg\/kg or with the positive control, diethyl-nitrosamine (DEN), at 2 mg\/kg by oral gavage on days 9 and 16 post birth and observed for approximately 1 year for the development of tumors. Plasma levels of clofibric acid after the second administration increased with dose, but were not dose proportional. Clofibrate administered by gavage on litter days 9 and 16 to neonatal mice at doses of 100, 250, or 500 mg\/kg did not produce a carcinogenic effect. The positive control DEN did produce tumors in the liver and lung (single and multiple adenomas and carcinomas) and harderian gland (adenoma) of both sexes. Non-neoplastic lesions related to DEN treatment were confined to myocardial degeneration\/fibrosis and testicular interstitial hyperplasia in males, and to glomerulonephrosis and gastritis in both sexes.<\/jats:p>","DOI":"10.1080\/10915810500210401","type":"journal-article","created":{"date-parts":[[2005,10,28]],"date-time":"2005-10-28T11:48:42Z","timestamp":1130500122000},"page":"341-348","source":"Crossref","is-referenced-by-count":8,"title":["Evaluation of the Carcinogenic Potential of Clofibrate in the Neonatal Mouse"],"prefix":"10.1177","volume":"24","author":[{"given":"Sarah R.","family":"Nesfield","sequence":"first","affiliation":[{"name":"GlaxoSmithKline, Safety Assessment, Ware, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas C.","family":"Williams","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Safety Assessment, Ware, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debie J.","family":"Hoivik","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Safety Assessment, Research Triangle Park, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard T.","family":"Miller","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Safety Assessment, Research Triangle Park, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane S.","family":"Allen","sequence":"additional","affiliation":[{"name":"Jane Allen Consulting, Inc, Raleigh, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Selinger","sequence":"additional","affiliation":[{"name":"Forest Laboratories Inc., Bioanalytical and Drug Metabolism Department, Farmingdale, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Rickert","sequence":"additional","affiliation":[{"name":"DerConsulting, Raleigh, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Santostefano","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Safety Assessment, Research Triangle Park, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2005,9,1]]},"reference":[{"key":"b1-0240341","doi-asserted-by":"publisher","DOI":"10.1177\/096032719401300201"},{"key":"b2-0240341","doi-asserted-by":"publisher","DOI":"10.1080\/01926230309800"},{"key":"b3-0240341","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-0322"},{"key":"b4-0240341","doi-asserted-by":"publisher","DOI":"10.1172\/JCI0214080"},{"key":"b5-0240341","doi-asserted-by":"publisher","DOI":"10.1006\/rtph.1997.1125"},{"key":"b6-0240341","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/12.8.1409"},{"key":"b7-0240341","volume-title":"Histopathology of preclinical toxicity studies","author":"Greaves P","year":"1990"},{"key":"b8-0240341","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgh182"},{"key":"b9-0240341","first-page":"102","author":"James NH","year":"1990","journal-title":"Toxicol Lett"},{"key":"b10-0240341","doi-asserted-by":"publisher","DOI":"10.1172\/JCI6223"},{"key":"b11-0240341","doi-asserted-by":"publisher","DOI":"10.1080\/713608372"},{"key":"b12-0240341","doi-asserted-by":"publisher","DOI":"10.1080\/15287398209530296"},{"key":"b13-0240341","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.13.7473"},{"key":"b14-0240341","doi-asserted-by":"publisher","DOI":"10.1080\/019262301753178537"},{"key":"b15-0240341","doi-asserted-by":"publisher","DOI":"10.1016\/0925-4439(95)00007-Q"},{"key":"b16-0240341","unstructured":"NDA1993Summary of basis for approval, Food and Drug Administration19304"},{"key":"b17-0240341","doi-asserted-by":"publisher","DOI":"10.1080\/10915810500210278"},{"key":"b18-0240341","first-page":"1211","volume":"36","author":"Reddy JK","year":"1976","journal-title":"Cancer Res"},{"key":"b19-0240341","doi-asserted-by":"publisher","DOI":"10.1080\/019262301753178438"},{"key":"b20-0240341","doi-asserted-by":"publisher","DOI":"10.1080\/019262301753178465"},{"key":"b21-0240341","doi-asserted-by":"publisher","DOI":"10.1289\/ehp.95103942"},{"key":"b22-0240341","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-1110(96)90016-0"},{"key":"b23-0240341","doi-asserted-by":"publisher","DOI":"10.1080\/10915810500210237"},{"key":"b24-0240341","doi-asserted-by":"publisher","DOI":"10.1080\/10915810500208199"},{"key":"b25-0240341","doi-asserted-by":"publisher","DOI":"10.1080\/10915810500208264"},{"key":"b26-0240341","volume-title":"Comparative toxicology of hypolipidemic fibrates","author":"Tucker MJ","year":"1995"},{"key":"b27-0240341","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041001"},{"key":"b28-0240341","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.4.1784"}],"container-title":["International Journal of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1080\/10915810500210401","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1080\/10915810500210401","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1080\/10915810500210401","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:22:14Z","timestamp":1777458134000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1080\/10915810500210401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["10.1080\/10915810500210401"],"URL":"https:\/\/doi.org\/10.1080\/10915810500210401","relation":{},"ISSN":["1091-5818","1092-874X"],"issn-type":[{"value":"1091-5818","type":"print"},{"value":"1092-874X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}